Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137852 · ClinicalTrials.gov registry record · Phase 2
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00137852 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 35 participants.
The verdict
NCT00137852, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a study for patients with resectable, locally advanced esophageal cancer. There is evidence to suggest that celecoxib in combination with cisplatin and irinotecan (CPT-11) may work well with radiation therapy to kill cancer cells. The primary goal is to develop a well-tolerated cancer treatment that has an acceptable response rate.
Interventions
- DRUG Cisplatin
- DRUG Celecoxib
- DRUG Irinotecan
- PROCEDURE Esophagectomy
- PROCEDURE Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2002-01 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137852
The ClinicalTrials.gov registry entry for NCT00137852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00137852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00137852 about?
NCT00137852 is a clinical study titled "Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer". This is a study for patients with resectable, locally advanced esophageal cancer. There is evidence to suggest that celecoxib in combination with cisplatin and irinotecan (CPT-11) may work well with radiation therapy to kill cancer cells. The primary goal is to develop a well-tolerated cancer treatm...
What is the current status of trial NCT00137852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2002-01. Estimated completion is 2017-09.
What interventions are being tested in trial NCT00137852?
The interventions under investigation include: Cisplatin (DRUG), Celecoxib (DRUG), Irinotecan (DRUG), Esophagectomy (PROCEDURE), Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00137852?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.